Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
UGT1A9 (Hepatocyte & Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone UGT1A9/1229 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IF, FC |
|---|---|
| Primary Accession | O60656 |
| Other Accession | 54600, 554822 |
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse / IgG2b, kappa |
| Clone Names | UGT1A9/1229 |
| Calculated MW | ~60kDa |
| Gene ID | 54600 |
|---|---|
| Other Names | UDP-glucuronosyltransferase 1-9, UDPGT 1-9, UGT1*9, UGT1-09, UGT1.9, 2.4.1.17, UDP-glucuronosyltransferase 1-I, UGT-1I, UGT1I, UDP-glucuronosyltransferase 1A9, lugP4, UGT1A9, GNT1, UGT1 |
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
| Precautions | UGT1A9 (Hepatocyte & Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | UGT1A9 (HGNC:12541) |
|---|---|
| Synonyms | GNT1, UGT1 |
| Function | [Isoform 1]: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:12181437, PubMed:15472229, PubMed:15470161, PubMed:18004212, PubMed:18052087, PubMed:18674515, PubMed:19545173). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:12181437, PubMed:18004212). Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol and estrone (PubMed:15472229). Also catalyzes the glucuronidation of the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties (PubMed:18052087, PubMed:19545173). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist caderastan, a drug which can inhibit the effect of angiotensin II (PubMed:18674515). Involved in the biotransformation of 7-ethyl-10- hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan (PubMed:12181437, PubMed:20610558). Also metabolizes mycophenolate, an immunosuppressive agent (PubMed:15470161, PubMed:18004212). |
| Cellular Location | Endoplasmic reticulum membrane; Single-pass membrane protein |
| Tissue Location | [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
It recognizes a protein of about 60kDa, which is identified as human UGT1A9. It does not cross-react with the other UGT1A isoforms including UGT1A7, UGT1A8, and UGT1A10 and shows a high degree of specificity. UGT1A9 is a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This MAb binds to human hepatocytes and the majority of human hepatocellular carcinomas (HCC s). In frozen sections, it stains hepatic cells and may be used as a marker of the liver. This MAb also binds to cell preparations of hepatocellular carcinoma biopsies or cell lines.
References
Shingo Oda, Miki Nakajima, Masahiko Hatakeyama, Tatsuki Fukami, and Tsuyoshi Yokoi. Preparation of a Specific Monoclonal Antibody against Human UDP-Glucuronosyltransferase (UGT) 1A9 and Evaluation of UGT1A9 Protein Levels in Human Tissues. Drug Metabolism and Disposition, 40:1620-1627, 2012
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
